GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). GeNeuro is developing a new approach for the treatment of MS by seeking to block a suspected source of the inflammatory and neurodegenerative components of the disease, rather than targeting the immune response of the body as do most current treatments.
This new approach is the result of 25 years of research on endogenous retroviruses, including 15 within bioMérieux and INSERM, before the creation of GeNeuro in 2006. This research has allowed us to discover and understand the action of a factor potentially causative of multiple sclerosis, the MSRV-Env protein, which is the envelope protein of a human endogenous retrovirus (HERV). The presence of MSRV-Env in the brains of patients may be an important cause of the inflammatory and neurodegenerative phenomena characterizing this disease.
GeNeuro thus has developed GNbAC1, a humanized monoclonal antibody, currently in Phase IIb clinical development in multiple sclerosis with the support of Servier, our principal partner. By neutralizing the MSRV-Env protein rather than targeting the patient's immune system, GNbAC1 could prove to be both safe and effective, and potentially able to slow or even halt the progression of the disease in all its forms.
GeNeuro also aims to develop its platform for other neurological diseases and autoimmune diseases such as type 1 diabetes and chronic inflammatory demyelinating polyneuropathy.
GeNeuro SA is a member of the Swiss Biotech Association, a member of the BioAlps community and has the CTI (Commission for Technology and Innovation) start-up label.
GeNeuro Innovation SAS is member of the French Lyon Biopole.